Long-term ACP-204 for Alzheimer's psychosis
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the previous ACP-204 study (trial ACP-204-006).
- You must be between 55 and 95 years old.
- You need a family member or friend who can go with you to all study visits and help out.
- Women need to be past menopause or unable to become pregnant. Men need to use reliable birth control.
- You cannot be in hospice care or bedridden.
- You must not have any major medical condition (other than Alzheimer's) that would make the study unsafe or hard to complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
This study tests a medication called ACP-204 for psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a long-term extension open to patients who completed a previous ACP-204 study, to see if the drug continues to be helpful and safe.
This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Hear when a new Alzheimer's Disease Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.